Jin Medical SEC Filings

Jin Medical International Ltd. reports operational progress at its new manufacturing facility in Chuzhou, Anhui Province, China. Its wholly owned subsidiary Zhongjin Medical Equipment (Anhui) Co., Ltd. has completed key regulatory steps, obtaining a license for Class I medical device production on December 29, 2025.

The Chuzhou facility, with approximately 430,000 square feet, is in the final construction phase and is projected to reach full-capacity production by the end of April 2026. Once fully operational, it is expected to provide annual capacity of 200,000 units of mid-to-high-end electric wheelchairs and senior mobility scooters.

Located in the Yangtze River Delta manufacturing hub, the facility is intended to enhance Jin Medical’s manufacturing scale, supply chain resilience, and ability to serve domestic and international demand. The company emphasizes that these expectations are forward-looking and subject to various business, regulatory, and economic risks.

Jin Medical International Ltd. filed a Form 6-K to share a press release announcing that its management team will host a fireside chat on February 1, 2026. The discussion will focus on the Company’s strategic priorities and considerations related to its capital structure, while also addressing recent market developments and the framework of its ongoing strategic planning efforts.

Management states that Jin Medical maintains what it believes is a strong liquidity position and is actively evaluating a range of strategic options aimed at enhancing its competitive position in the rehabilitation medical equipment industry. The Company presents these initiatives as being undertaken from a position of operational and financial strength, and highlights its established manufacturing footprint and distribution network in China and international markets.

Jin Medical International Ltd. has called a 2026 extraordinary general meeting on January 30, 2026 to ask shareholders to approve a major overhaul of its capital structure and governance documents. The company proposes creating a dual-class share structure with 900,000,000 Class A ordinary shares carrying one vote each and 100,000,000 Class B ordinary shares carrying thirty votes each. As part of this recapitalization, it plans to issue approximately 136,547,100 Class A shares pro rata to existing shareholders (other than Jolly Harmony Enterprises Limited) and approximately 20,000,000 Class B shares to Jolly Harmony, then repurchase and cancel the current 156,547,100 ordinary shares.

Shareholders are also being asked to approve new second amended and restated memorandum and articles of association to reflect the dual-class structure, and to authorize up to three potential share consolidations over the next two years, each triggered at the Board’s discretion when the Class A share price is below US$1.00. In addition, the Board seeks approval of a 2026 Equity Incentive Plan allowing issuance of up to 13,000,000 Class A shares as equity awards, and authority to adjourn the meeting if more time is needed to secure votes. The Board unanimously recommends voting in favor of all five proposals.

Jin Medical International Ltd. submitted a Form 6‑K that attaches unaudited condensed consolidated financial statements covering the periods ended March 31, 2024 and the six months ended March 31, 2025 and March 31, 2024. The filing also includes an Operating and Financial Review and Prospects tied to those six‑month results and standard Inline XBRL exhibits (Instance, taxonomy extensions, calculation, definition, label, presentation) for interactive data. The document contains customary forward‑looking statement language about assumptions on revenue, income, cash balances, financing needs, hiring, competition, and expansion risks. The filing is signed by Erqi Wang, Chief Executive Officer, and Ziqiang Wang, Chief Financial Officer, dated August 20, 2025.

Jin Medical International Ltd. (Nasdaq: ZJYL) has filed a Form F-3 universal shelf registration that would allow it to issue up to $300 million of ordinary shares, warrants, debt securities, rights or units on a continuous or delayed basis. The filing gives the company maximum flexibility in timing, structure and pricing of future capital raises. Each specific offering will be detailed in a subsequent prospectus supplement.

The company’s current public float is approximately $34.4 million (based on 37.8 million non-affiliate shares at $0.91 on 30 Apr 2025). Because its float is below $75 million, General Instruction I.B.5 limits aggregate primary offerings under the F-3 to one-third of public float in any 12-month period—about $11.5 million at today’s level. Ordinary shares last traded at $0.6594 on 24 Jun 2025.

Jin Med is a Cayman holding company; operations are conducted in China through a variable-interest-entity (VIE), Changzhou Zhongjin Medical Equipment Co. Ltd. Investors buy equity in the Cayman entity and have only contractual, not ownership, exposure to the PRC operating company. The prospectus emphasizes extensive regulatory and enforcement risks associated with this structure, including potential PRC disallowance that could render the securities worthless.

The filing states the company is an emerging growth company; it is not currently subject to CAC cybersecurity review and, as an existing overseas issuer, is not immediately required to file with the CSRC for the shelf registration. Future offerings, however, must be filed with the CSRC within three business days of completion.

Key investor takeaways:

• Shelf capacity: up to $300 million, but annual usage capped by I.B.5.
• Potential dilution risk given current float and low share price.
• Material VIE, PRC policy and regulatory uncertainties.
• No immediate CAC or CSRC obstacles identified as of 15 May 2025.

Jin Medical International Ltd. (NASDAQ: ZJYL) filed a Form 6-K announcing the appointment of Dr. James Jiayuan Tong, age 51, as an Independent Director. Effective 20 June 2025, Dr. Tong becomes Chair of the Nominating & Corporate Governance Committee and joins the Audit and Compensation Committees, thereby increasing the proportion of independent oversight on all three key board panels.

Dr. Tong brings more than 20 years of cross-border experience in finance, investment banking, healthcare and academic research. Recent roles include founder of ThorBay Holdings (2022-present) and Venture Partner at Korea Investment Partners (2019-2022) with a focus on oncology, AR/VR, AI healthcare, medical devices and pre-IPO strategy. He has previously served as CFO and venture partner in both public and private companies, and has managed SEC compliance and M&A processes—skills directly relevant to committee responsibilities. Dr. Tong holds an M.D. from Peking University Health Science Center (1996) and a Ph.D. in Neuroscience from Stony Brook University (2001). There are no family relationships or related-party transactions requiring disclosure under Regulation S-K Item 404. The filing is expressly not incorporated by reference into other SEC filings.

The addition of an experienced, fully independent director with deep financial and healthcare expertise should strengthen Jin Medical’s governance framework and may enhance investor confidence; however, the filing contains no financial data or immediate operational changes.